The remarkable success of sulfanilamide (para-aminobenzenesulfonamide) and its derivatives in the treatment of experimental and human infections due to beta hemolytic streptococci, and to some extent of those due to pneumococci, has given rise to the hope that these preparations will prove effective in the treatment of streptococcic and pneumococcic meningitis, especially in view of the high mortality of these diseases (as high as 97 per cent in the case of streptococcic meningitis, as shown in a recent survey by Gray1).
In February 1936 Caussé, Loiseau and Gisselbrecht2 reported the recovery of a man with streptococcic meningitis of otitic origin following the intravenous and oral administration of a derivative of sulfanilamide (prontosil). The experimental work reported here was begun in January 1937, immediately after the publication of the paper by Long and Bliss3 on the remarkable effects in the treatment of mice with septicemia due to beta hemolytic streptococci. Since
KOLMER JA, RULE AM, WERNER ML. SULFANILAMIDE IN THE TREATMENT OF EXPERIMENTAL STREPTOCOCCIC AND PNEUMOCOCCIC MENINGITIS. Arch Otolaryngol. 1938;27(5):519–534. doi:10.1001/archotol.1938.00650030532001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: